China
Chinese medical imaging business secures $86m Series B
Shanghai-based Universal Medical Imaging, China’s largest independent imaging diagnosis company has raised a RMB600 million ($86 million) Series B round led by Cathay Capital, V Star Capital and CEC Capital.
Deal focus: Lightspeed targets solid-state LiDAR
Having assessed some 40 autonomous driving companies globally, Lightspeed China Partners decided that Hesai - a business born in the US and raised in China - is best-placed to take the technology forwards
PE-backed Akeso Biopharma targets Hong Kong IPO
Chinese biotech player Akeso Biopharma has made a second attempt at filing for a Hong Kong IPO after its previous application was rejected last month for failing to meet regulatory requirements.
AVCJ Awards 2019: Deal of the Year - Small Cap: AffaMed Therapeutics
CBC Group established biosimilars specialist AffaMed Therapeutics to remove uncertainties in the development process and to tap Chinese demand for affordable treatments
Joy Capital leads $88m round for China's Shihuituan
Joy Capital has announced its participation - as the lead investor - in an $88.3m funding round for Chinese community group buying platform Shihuituan, which is also known as Nice Tuan.
Chinese genetic testing player for infectious diseases gets Series B+
Chinese genetic testing specialist Genskey raised an RMB50 million ($7.1m) extended Series B round of funding led by Shenzhen-based Fortune Capital. Existing investor Legend Capital re-upped.
Japan's TDK invests air mobility developer
Japan’s TDK Corporation has made a VC commitment of undisclosed size in AutoFlightX, an electric air mobility company based in Germany with a significant China presence.
Raffles Family Office backs Hong Kong co-working space player
Hong Kong-based multi-family office Raffles Family Office will invest $15 million in local co-working space operator WorkTech.
AVCJ Awards 2019: Firm of the Year - Mid Cap: Centurium Capital
China-focused Centurium Capital has enjoyed a productive 12 months, closing its debut US dollar fund, deploying most of the capital, and securing an early liquidity event
China-US tensions: Adapting to malaise
China would suffer the most immediate impact of a technology decoupling with the US, but both sides would be damaged in the long-term in the absence of remedial action
CITIC Capital targets OBOR deals with blank check company
CITIC Capital has launched a special purpose acquisition vehicle (SPAC) – or blank check company – on the New York Stock Exchange to pursue deals under its One Belt One Road (OBOR) strategy.
Centurium leads $100m Series D for China's Yunxuetang
Yunxuetang, an online corporate training services provider focused on China, has raised $100 million in Series D funding led by Centurium Capital. Existing investors Yunfeng Capital and SIG both re-upped.
Warburg Pincus returns $2b from China portfolio in 2019
Warburg Pincus generated distributions of $2 billion from its China investments last year, a record annual total for its local operation.
CITIC Capital seeks to increase McDonald's China stake
CITIC Capital is bidding for a 22% stake in the McDonald’s China and Hong Kong business held by CITIC Group, formerly its parent and now one of several shareholders.
Profile: Joy Capital's Erhai Liu
First at Legend Capital and now at Joy Capital, Erhai Liu has demonstrated a knack for spotting emerging technology trends in China and helping founders navigate the challenges of entrepreneurialism
Green Pine leads Series B for Chinese gene testing player
Chinese gene testing business AmCare Genomics Lab has raised RMB110 million ($16 m) in Series B funding led by Green Pine Capital Partners. This comes four months after the company closed an extended Series A round of RMB30 million.
Centurium backs China logistics player
Centurium Capital has invested $300 million in ANE Logistics, one of the largest LTL (Less-than-truckload) operators in China.
AVCJ Awards 2019: Deal of the Year - Mid Cap: Hangzhou UCO Cosmetics
CITIC Capital’s acquisition of Hangzhou UCO Cosmetics was predicated on the rise of China’s beauty industry, but it is also part of a broader ecosystem play
AVCJ Awards 2019: Exit of the Year - IPO: Innovent Biologics
Innovent Biologics has set a new standard for Chinese biotech, securing an innovative drug development tie-up with Eli Lilly and then completing a successful Hong Kong listing
China's Danke raises $130m in scaled back IPO
Chinese apartment rental platform Danke raised about $130 million in a smaller-than-expected US IPO that was primarily underwritten by existing private equity investors.
China's I-Mab falls on US debut after $104m IPO
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
China Feihe gains drive Morgan Stanley's investment revenue
Projected carried interest payments from Morgan Stanley Private Equity Asia’s (MSPEA) investment in Chinese dairy products company China Feihe were largely responsible for a near fivefold increase in annual investment revenue for the parent bank.
Chinese 3D map provider raises $14m
Airlook, a Chinese three-dimensional map provider, has raised nearly RMB100 million ($14 million) in an extended Series B round led by GF Qianhe, the alternative investment arm of Hong Kong-listed GF Securities.
AVCJ Awards 2019: Firm of the Year - Large Cap: PAG
China’s private consumption story continues to be a driving force for PAG Asia Capital. The GP also won prizes for Deal of the Year - Large Cap and Fundraising of the Year - Large Cap